509 AS-252424 is a specific and targeted ACSL4 inhibitor that binds directly to the glutamine 464 of ACSL4 to inhibit its enzymatic activity, thereby inhibiting lipid peroxidation and ferroptosis, effectively alleviating ferroptosis-mediated organ damage in mouse models, including I/R-induced kidney injury and acute liver injury
When I spoke with Julie Stich, CEBS, Vice President of Content at the International Foundation, she said that with the release of new FDA approvals and clinical studies, and increasing demand and awareness, employers are seriously considering how to proceed with drug coverage policies in response
The liposomal delivery system protects the compound from stomach acid and dramatically enhances cellular uptake
All infusions are physician-supervised, HSA/FSA eligible, and delivered to your home, hotel, or office with no clinic visit required